title: Novel potential therapies for septic shock.
abstract: Sepsis is the systemic inflammatory response syndrome secondary to a local infection. Septic shock, the severe complication of sepsis associated with refractory hypotension, is frequently a near-fatal condition requiring prompt diagnosis and management. Although the recent years have been associated with considerable improvements in the knowledge of the pathophysiology of the disease and remarkable advances have been achieved in sepsis treatment, the morbidity and mortality of this disease are still unacceptably high. In this review, we will briefly discuss the ongoing standard treatment of septic shock and describe novel potential therapies, aiming to improve hemodynamic support and/or control inflammatory response in sepsis. These therapies were associated with benefits in experimental studies and have been tested or are currently under testing in randomized controlled studies with septic patients.
authors.forename: Luciano Cesar Pontes
authors.initials: LC
authors.lastname: Azevedo
authors.forename: Marcelo
authors.initials: M
authors.lastname: Park
authors.forename: Guilherme Paula Pinto
authors.initials: GP
authors.lastname: Schettino
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D006440:Hemofiltration; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism; D007136:Immunoglobulins / Q000378:metabolism / Q000627:therapeutic use; D007249:Inflammation; D008954:Models, Biological; D018805:Sepsis; D012772:Shock, Septic / Q000175:diagnosis* / Q000382:microbiology / Q000628:therapy*; D016896:Treatment Outcome; D014667:Vasopressins / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007136:Immunoglobulins; D014667:Vasopressins